LDN-193189 HCl

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598524

CAS#: 1435934-00-1 (dihydrochloride)

Description: LDN-193189 is a highly potent small molecule BMP inhibitor with IC50 of 5 and 30 nM for ALK2 and ALK3, respectively. LDN193189 also inhibits BMP type I receptors ALK6 (TGFβ1/BMP signaling) and subsequent SMAD phosphorylation.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 250 2 Weeks
10mg USD 420 2 Weeks
25mg USD 750 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-07-07. Prices are subject to change without notice.

LDN-193189 HCl purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 598524
Name: LDN-193189 HCl
CAS#: 1435934-00-1 (dihydrochloride)
Chemical Formula: C25H24Cl2N6
Exact Mass:
Molecular Weight: 479.409
Elemental Analysis: C, 62.63; H, 5.05; Cl, 14.79; N, 17.53

Related CAS #: 1062368-24-4 (free base)   1062368-62-0 (HCl)   1435934-00-1 (dihydrochloride)  

Synonym: LDN-193189 monohydrochloride; LDN-193189 HCl; LDN193189; LDN-193189; LDN 193189; LDN193189; DM-3189; DM 3189; DM3189;

IUPAC/Chemical Name: 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline dihydrochloride


InChi Code: InChI=1S/C25H22N6.2ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;;/h1-10,15-17,26H,11-14H2;2*1H

SMILES Code: [H]Cl.[H]Cl.C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Horbelt D, Boergermann JH, Chaikuad A, Alfano I, Williams E, Lukonin I, Timmel T, Bullock AN, Knaus P. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290(6):3390-404. doi: 10.1074/jbc.M114.604397. Epub 2014 Nov 3. PubMed PMID: 25368322; PubMed Central PMCID: PMC4319009.

2: Ali JL, Lagasse BJ, Minuk AJ, Love AJ, Moraya AI, Lam L, Arthur G, Gibson SB, Morrison LC, Werbowetski-Ogilvie TE, Fu Y, Nachtigal MW. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells. Int J Cancer. 2015 Mar 1;136(5):E455-69. doi: 10.1002/ijc.29220. Epub 2014 Sep 26. PubMed PMID: 25227893.

3: Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010 Nov;42(11):1802-7. doi: 10.1016/j.biocel.2010.07.018. Epub 2010 Aug 5. PubMed PMID: 20691279.

4: Derwall M, Malhotra R, Lai CS, Beppu Y, Aikawa E, Seehra JS, Zapol WM, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):613-22. doi: 10.1161/ATVBAHA.111.242594. Epub 2012 Jan 5. PubMed PMID: 22223731; PubMed Central PMCID: PMC3679546.

5: Malhotra R, Burke MF, Martyn T, Shakartzi HR, Thayer TE, O'Rourke C, Li P, Derwall M, Spagnolli E, Kolodziej SA, Hoeft K, Mayeur C, Jiramongkolchai P, Kumar R, Buys ES, Yu PB, Bloch KD, Bloch DB. Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency. PLoS One. 2015 Jan 20;10(1):e0117098. doi: 10.1371/journal.pone.0117098. eCollection 2015. PubMed PMID: 25603410; PubMed Central PMCID: PMC4300181.

6: Lai Y, Xie C, Zhang S, Gan G, Wu D, Chen W. Bone morphogenetic protein type I receptor inhibition induces cleft palate associated with micrognathia and cleft lower lip in mice. Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):612-23. doi: 10.1002/bdra.23504. Epub 2016 May 6. PubMed PMID: 27150428.

7: Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell Signal. 2011 Nov;23(11):1831-42. doi: 10.1016/j.cellsig.2011.06.019. Epub 2011 Jun 29. PubMed PMID: 21740966.

8: Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, Hill CS, Bullock AN. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013 Apr 30;8(4):e62721. doi: 10.1371/journal.pone.0062721. Print 2013. PubMed PMID: 23646137; PubMed Central PMCID: PMC3639963.

9: Yamasaki A, Kasai A, Toi A, Kurita M, Kimoto S, Hayata-Takano A, Nakazawa T, Nagayasu K, Shintani N, Hashimoto R, Ito A, Meltzer HY, Ago Y, Waschek JA, Onaka Y, Matsuda T, Baba A, Hashimoto H. Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro. J Neurochem. 2015 Feb;132(4):418-28. doi: 10.1111/jnc.12999. Epub 2015 Jan 23. PubMed PMID: 25421849.

10: Theurl M, Nairz M, Schroll A, Sonnweber T, Asshoff M, Haschka D, Seifert M, Willenbacher W, Wilflingseder D, Posch W, Murphy AT, Witcher DR, Theurl I, Weiss G. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica. 2014 Sep;99(9):1516-24. doi: 10.3324/haematol.2013.099481. Epub 2014 Jun 3. PubMed PMID: 24895335; PubMed Central PMCID: PMC4562542.

11: Ahsan S, Ge Y, Tainsky MA. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget. 2016 Aug 30;7(35):57171-57185. doi: 10.18632/oncotarget.11036. PubMed PMID: 27494873; PubMed Central PMCID: PMC5302981.

12: Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, Rauwerdink KM, Winn JC, Saez B, Cook CM, Szekely BA, Roy CN, Seehra JS, Cuny GD, Scadden DT, Peterson RT, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011 May 5;117(18):4915-23. doi: 10.1182/blood-2010-10-313064. Epub 2011 Mar 10. PubMed PMID: 21393479; PubMed Central PMCID: PMC3100698.

13: Zeng H, Ortiz A, Shen PF, Cheng CJ, Lee YC, Yu G, Lin SC, Creighton CJ, Yu-Lee LY, Lin SH. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget. 2017 Feb 7;8(6):10145-10160. doi: 10.18632/oncotarget.14358. PubMed PMID: 28052036; PubMed Central PMCID: PMC5354648.

14: Tadokoro T, Gao X, Hong CC, Hotten D, Hogan BL. BMP signaling and cellular dynamics during regeneration of airway epithelium from basal progenitors. Development. 2016 Mar 1;143(5):764-73. doi: 10.1242/dev.126656. Epub 2016 Jan 25. PubMed PMID: 26811382; PubMed Central PMCID: PMC4813333.

15: Gomez-Stallons MV, Wirrig-Schwendeman EE, Hassel KR, Conway SJ, Yutzey KE. Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification. Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1398-405. doi: 10.1161/ATVBAHA.116.307526. Epub 2016 May 19. PubMed PMID: 27199449; PubMed Central PMCID: PMC4919184.

16: Shahid M, Spagnolli E, Ernande L, Thoonen R, Kolodziej SA, Leyton PA, Cheng J, Tainsh RE, Mayeur C, Rhee DK, Wu MX, Scherrer-Crosbie M, Buys ES, Zapol WM, Bloch KD, Bloch DB. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2016 Apr 15;310(8):H984-94. doi: 10.1152/ajpheart.00879.2015. Epub 2016 Feb 12. PubMed PMID: 26873969; PubMed Central PMCID: PMC4867336.

17: Kanamori Y, Murakami M, Matsui T, Funaba M. The regulation of hepcidin expression by serum treatment: requirements of the BMP response element and STAT- and AP-1-binding sites. Gene. 2014 Nov 10;551(2):119-26. doi: 10.1016/j.gene.2014.08.037. Epub 2014 Aug 21. PubMed PMID: 25151311.

18: Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, Cappellini MD, Weiss G, Hong CC, Lin HY, Babitt JL. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant. 2013 Jul;28(7):1733-43. doi: 10.1093/ndt/gfs584. Epub 2013 Jan 22. PubMed PMID: 23345622; PubMed Central PMCID: PMC3707526.

19: Nahar-Gohad P, Gohad N, Tsai CC, Bordia R, Vyavahare N. Rat aortic smooth muscle cells cultured on hydroxyapatite differentiate into osteoblast-like cells via BMP-2-SMAD-5 pathway. Calcif Tissue Int. 2015 Apr;96(4):359-69. doi: 10.1007/s00223-015-9962-z. Epub 2015 Mar 1. PubMed PMID: 25725805; PubMed Central PMCID: PMC4393885.

20: Cook BD, Evans T. BMP signaling balances murine myeloid potential through SMAD-independent p38MAPK and NOTCH pathways. Blood. 2014 Jul 17;124(3):393-402. doi: 10.1182/blood-2014-02-556993. Epub 2014 Jun 3. PubMed PMID: 24894772; PubMed Central PMCID: PMC4102711.